# Treatment Options for Metastatic Prostate Cancer
The treatment of metastatic prostate cancer depends on the stage of the disease and how the cancer responds to hormonal therapy. Treatments are aimed at slowing growth, relieving symptoms, and maintaining quality of life. The main forms of treatment are described here.
Hormonal Therapies (Androgen Deprivation Therapy)
Hormonal therapy is the foundation of treatment for metastatic prostate cancer. Men receive medications that lower testosterone levels or block the action of testosterone.
**Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists**
These medications suppress testosterone production by the testes. They work through the brain and ensure that signals to the testes are interrupted. The treatment must be administered regularly (for example, monthly or every three months via injections).
ProveniIncluded in official guidelines, or approved by EMA or FDA
Side effects may include hot flashes, night sweats, reduced libido, and erectile dysfunction. Some men experience weight gain, fatigue, or mood changes. With long-term use, bone density loss and muscle loss may occur.
Anti-Androgens (First Generation)
Bicalutamide and flutamide block the receptor where testosterone acts on cancer cells. They are often combined with GnRH therapy.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Side effects are similar to those of GnRH therapy, supplemented with possible breast tenderness and abdominal complaints.
New Androgen Receptor Targeted Inhibitors (ARTI)
Medications such as enzalutamide, apalutamide, and darolutamide are newer agents that bind much more strongly to the androgen receptor in cancer cells. These are usually given in combination with GnRH therapy, especially in the early stages of metastatic disease.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Studies have shown that these combinations delay disease-related death and extend overall survival compared to GnRH therapy alone. Side effects include fatigue, abdominal complaints, diarrhea, and in rare cases, men have reported stroke or heart rhythm disorders for the first time.
Chemotherapy
Docetaxel and cabazitaxel are chemotherapies used at certain stages of metastatic prostate cancer, particularly when the cancer has become resistant to hormonal therapy (castration-resistant).
**Docetaxel**
Docetaxel is a taxane that slows the division rate of cancer cells by damaging microtubules in cells. It is administered intravenously.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Docetaxel can extend life expectancy, especially in the early stages of castration-resistant disease. Side effects include hair loss, low white blood cell counts (infection risk), nausea, diarrhea or constipation, and tingling in fingers and toes. Some men experience severe fatigue.
**Cabazitaxel**
Cabazitaxel is another taxane, usually used after docetaxel has been administered. It works in the same way: it disrupts the division cycle of cancer cells.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Side effects are similar to those of docetaxel, particularly neutropenia (low white blood cell counts), risk of infections, nausea, and fatigue.
Radioligand Therapy
Lutetium-177 PSMA radioligand therapy is a targeted treatment that has been increasingly used recently for castration-resistant prostate cancer with bone metastases.
**Lutetium-177 PSMA Radioligand Therapy**
This is a radiotherapy in which a radioactive particle (lutetium-177) is introduced into the bloodstream via injection. The particle binds to proteins (PSMA) on cancer cells, particularly in bone and lymph node metastases. The radioactivity damages these cancer cells from within.
ProveniIncluded in official guidelines, or approved by EMA or FDA
A recent summarizing analysis of studies shows that this therapy can reduce pain and slow disease-related mortality, especially in men with bone metastases. Side effects include fatigue, nausea, dry mouth, and in some cases temporary reduction in certain blood cell counts. Radioactive exposure is limited and locally targeted; long-term effects are still being investigated.
Radium-223
Radium-223 is an alpha radiation source that accumulates in bone metastases and damages them from within.
**Radium-223**
This agent is administered intravenously in multiple treatments (usually six injections at weekly intervals). It works primarily on bone metastases and is used in the castration-resistant stage.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Radium-223 can reduce pain and extend overall life expectancy. Side effects are generally limited but can include low blood cell counts (with risk of infection or bleeding), diarrhea, and fatigue.
Supportive treatments
**Bone protectors (bisphosphonates and RANK-ligand inhibitors)**
In men with extensive bone metastases, bone protectors can be used to prevent bone fractures and relieve bone pain. These work by slowing the rate of bone breakdown.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Side effects can include jaw problems (with long-term use), joint pain, and very rarely bone fractures with delayed healing.
**Pain management**
As the disease progresses, pain management with opioids may be necessary, together with additional medications for nausea and constipation.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Pain relievers are tailored to the severity of pain. Side effects depend on the chosen agent and can include fatigue, bowel problems, and sleep changes.
**Radiotherapy targeting specific metastases**
External radiation can be locally targeted at painful bone metastases or brain metastases to relieve pain and prevent neurological symptoms.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Side effects depend on the irradiated area and can include skin rash, fatigue, and in the case of brain radiation, sometimes memory or concentration problems.
Therapies under investigation
**Biomarker-guided therapy and genomic testing**
Some studies are investigating whether tests for genetic abnormalities in tumors help better choose which therapy is most effective. This is a current research area but not yet routinely available.
ResearchediPositive results in clinical studies, not yet standard treatment
**Combination therapies with radium-223 and enzalutamide**
Early data suggest that combining radium-223 with certain androgen-receptor inhibitors may offer benefits, but this is still being investigated in large clinical trials.
ResearchediPositive results in clinical studies, not yet standard treatment
**Bipolar androgen therapy**
This is an experimental approach in which androgen blockade and androgen addition are alternated, with the aim of restoring sensitivity to therapy. This is currently being studied.
ExperimentaliOngoing in study setting, outcome still unknown
**New androgen-receptor inhibitors (Xaluritamig)**
Newer agents in this class are being investigated for men who have become resistant to existing therapies.
ResearchediPositive results in clinical studies, not yet standard treatment
When and why treatments change
In the early stage of metastatic disease (hormone-sensitive), men typically receive a combination of GnRH therapy and a newer androgen-receptor inhibitor. This combination extends the time before the disease becomes resistant.
After months or years, the cancer may become resistant to these hormone treatments (castration-resistant). At that point, treatments shift to chemotherapy (docetaxel or cabazitaxel), radioligand therapy, or radium-223, depending on where metastases are located, how quickly the disease progresses, and how well the man tolerates side effects.
With all treatments, regular contact with the treatment team is important. Blood tests and imaging help determine whether a treatment is still working or adjustments are needed.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._